Recent 8-K filings for GRI
Highest-materiality recent filing
GRI Bio announces positive Phase 2a topline results for GRI-0621 in IPF
- Primary endpoint met: GRI-0621 well tolerated with no drug-related severe/serious adverse events; no GI increase vs placebo.
- Biomarkers improved: type VI collagen remodeling shifted from fibrogenic (+10%) to fibrolytic (-7%), suggesting fibrosis resolution.
-
GRI Bio Q1 net loss $2.0M; Phase 2a data show zero cough, improved lung function in IPF
Net loss of $2.0M for Q1 2026 vs. $3.0M in Q1 2025; cash $11.0M, runway into Q2 2027.
-
GRI Bio reiterates FY2025 results: $8.2M cash, $12M loss; raises $6.5M, runway into Q1 2027
Cash and cash equivalents of $8.2M at Dec 31, 2025; raised additional $6.5M in Jan 2026 via ATM offering.
-
GRI Bio expands ATM equity offering capacity from $10M to $60M via H.C. Wainwright amendment
Amendment to At The Market Offering Agreement increases aggregate offering price to $60 million.
-
GRI Bio reports positive Phase 2a gene expression data for GRI-0621 in IPF
Phase 2a gene expression data shows significant improvements in lung injury, fibroblast activation, and fibrosis-resolution genes vs placebo.
-
GRI Bio announces 1-for-28 reverse stock split effective Jan 23, 2026 to regain Nasdaq compliance
Stockholders approved reverse split at January 15, 2026 special meeting.
-
GRI Bio conditionally regains Nasdaq equity compliance after prior deficiency
Nasdaq Staff notified GRI Bio on Jan 15, 2026 that it conditionally regained compliance with the Stockholders' Equity Requirement (Nasdaq Listing Rule 5550(b)(1)).
-
Shareholders approved reverse stock split at ratio between 1:2 and 1:30, with board discretion to set exact ratio or abandon.
-
GRI Bio increases ATM offering capacity to $7.38M, waives Dec 2025 SPA restrictions
Increased ATM capacity by up to $7.38M in common stock; $6.17M already sold under the program.
-
GRI Bio reports positive Phase 2a immune data for GRI-0621 in IPF
Phase 2a data shows GRI-0621 reduces pro-fibrotic cytokines (IL-4, IL-13, IL-17A, IL-22, TGF-β) and increases anti-fibrotic IFN-γ in BAL and PBMC after 12 weeks.
-
GRI Bio launches $6.7M public offering of common stock and warrants
Offering comprises 2.6M shares, 8.1M pre-funded warrants ($0.0001/share), and 10.7M Series F warrants ($0.75/share) at $0.75 per unit.
-
GRI Bio closes $8.0M public offering of common stock and Series F warrants
Offering of 10,666,667 shares (or equivalents) plus Series F warrants to buy same number at $0.75/share.
-
GRI Bio announces positive Phase 2a topline results for GRI-0621 in IPF
Primary endpoint met: GRI-0621 well tolerated with no drug-related severe/serious adverse events; no GI increase vs placebo.
-
GRI Bio reports positive Phase 2a data for GRI-0621 in IPF; primary endpoint met
Phase 2a trial (35 IPF subjects, 2:1 randomization) met primary safety endpoint; GRI-0621 well tolerated over 12 weeks with no treatment-related SAEs.
-
GRI BIO receives Nasdaq delisting notice for stockholders' equity deficiency
Nasdaq notified GRI BIO of non-compliance with minimum stockholders' equity requirement (Listing Rule 5550(b)(1)).
-
GRI Bio files corporate presentation with no material new disclosures
Furnished a corporate presentation dated August 20, 2025 under Regulation FD.
-
Shareholders approve 400,000-share increase to GRI Bio's 2018 Equity Incentive Plan
Shareholders voted 48,362 to 17,889 (179 abstain) to approve the amendment; broker non-votes: 1,023,943.
-
6-week interim data from Phase 2a study of GRI-0621 in IPF show reduced fibrogenesis and increased fibrolysis in treated patients.
-
IDMC recommends study continue after no safety concerns in first 24 patients evaluated at 6 weeks.
-
GRI Bio increases ATM offering capacity by $1.76M after selling $4.55M previously
Filed prospectus supplement to increase maximum shares issuable under ATM to $1,758,934.
-
GRI Bio reports Q1 net loss $3.0M; GRI-0621 Phase 2a IPF trial on track for data in Q2/Q3 2025
Net loss of $3.0M for Q1 2025; R&D expenses $1.6M, G&A $1.4M.
-
GRI Bio increases ATM offering capacity by up to $1.67M, on top of $3.6M already sold
Prospectus supplement filed to increase ATM issuance by up to $1.67M, on top of $3.6M previously sold.
-
GRI Bio dismisses auditor Sadler Gibb, appoints WithumSmith+Brown as new independent accountant.
Audit Committee dismissed Sadler Gibb on April 11, 2025; no disagreements on accounting principles or practices.
-
GRI Bio prices $5M public offering of shares and warrants; net proceeds ~$4.2M
Priced public offering of 1,388,888 units at $3.60 each (share or pre-funded warrant plus Series E-1, E-2, E-3 warrants).
-
GRI Bio reports FY2024 net loss of $8.2M; cash runway into Q2 2025
Net loss of $8.2M for FY2024; R&D spend increased 19% to $3.8M; G&A fell 45% to $4.5M.
-
GRI Bio regains compliance with Nasdaq minimum bid price rule
Received Nasdaq notice on March 10, 2025 confirming compliance with Listing Rule 5550(a)(2).
-
GRI Bio announces 1-for-17 reverse stock split effective Feb 21, 2025
Reverse split at 1:17 ratio, effective 4:01 p.m. ET on Feb 21, 2025; post-split trading begins Feb 24, 2025 on Nasdaq under symbol GRI.
-
GRI Bio shareholders authorize reverse stock split at ratio of 1:2 to 1:23
Special meeting held Feb 11, 2025; quorum of 4,640,469 shares (51.94%) present.
-
GRI Bio increases at-the-market offering capacity to $322,468 after $3.6M already sold
On December 20, 2024, GRI Bio filed a prospectus supplement to increase shares issuable under its ATM agreement with H.C. Wainwright to up to $322,468.
-
GRI Bio reports Q3 net loss of $6.3M; cash runway extended into mid Q1 2025
Net loss of $6.3M for nine months ended Sep 30, 2024; R&D expenses $2.9M.
-
GRI Bio raises $13.9M in gross proceeds since Jan 2024; cash runway into mid Q1 2025
Closed Oct 22 warrant exercise for 762,236 shares raising $0.8M gross proceeds.
-
GRI Bio amends warrants; raises $0.8M by reducing exercise price to $1.00
Entered repricing agreements for 762,236 Series B warrants; holders exercise at $1.00/share (down from $14.30) for gross proceeds of $762,236.
-
Received Nasdaq letter on Sept 10, 2024 for failing minimum bid price of $1.00 over 30 consecutive business days.
-
GRI Bio receives Nasdaq deficiency notice for minimum bid price non-compliance
Received Nasdaq letter on Sept 10, 2024; closing bid price below $1.00 for 30 consecutive business days.
-
GRI Bio shareholders reject equity plan increase by 600K shares; director David Baker elected
David Baker elected Class I director with 61,134 for vs 40,091 against (155 abstain).
-
GRI Bio adjourns 2024 annual meeting to Sept 6 to solicit more proxies for outstanding proposals
Only 34.58% of shares present (256,566 of 741,914); quorum was barely met at one-third threshold.
-
GRI Bio Q2 net loss $2.4M; cash runway into Q1 2025; Phase 2a IPF data on track
Net loss of $2.4M for Q2 2024; R&D expense $0.9M; G&A expense $1.4M (down from $5.1M YoY).
-
GRI Bio increases ATM offering capacity to $2.64M, reports $961K already sold
Maximum aggregate gross proceeds from ATM offering raised to $2,644,609 via prospectus supplement filed July 26, 2024.
-
GRI Bio increases ATM offering capacity by up to $1.04M, excluding prior $0.96M sales
Increased maximum aggregate sales price of shares under ATM agreement with H.C. Wainwright to $1,038,886, excluding $961,272 already sold.
-
GRI Bio regains compliance with Nasdaq continued listing standards
Received Nasdaq notice on July 2, 2024 curing equity deficiency under Listing Rule 5550(b).
-
GRI Bio prices $4.0M public offering of shares and warrants at $1.83/unit
Offering of 2,185,793 shares (or equivalents) plus Series C-1 and C-2 warrants at $1.83 per unit.
-
GRI Bio CMO Albert Agro reduced to 70 hrs/month, salary cut to $100k
CMO Albert Agro's base salary reduced from $325,000 to $100,000 annually.
-
GRI Bio announces 1-for-13 reverse stock split to regain Nasdaq compliance
Reverse split at 1-for-13 effective 4:01 p.m. ET June 17, 2024; split-adjusted trading starts June 18, 2024.
-
GRI Bio stockholders approve reverse stock split in range of 1:2 to 1:15
Proposal 1 approved: 1,417,003 votes for, 310,490 against, 120 abstained.
-
GRI Bio receives Nasdaq delisting determination; plans to appeal by May 28, 2024
Received Nasdaq Staff determination letter on May 21, 2024, for non-compliance with stockholders' equity rule (Rule 5550(b)) after initial 180-day cure period ended May 20, 2024.
-
GRI Bio enters into ATM equity offering agreement with H.C. Wainwright for up to $961,579
Company may sell up to $961,579 of common stock through H.C. Wainwright as sales agent.
-
GRI Bio reports Q1 net loss $1.9M; cash $4.1M; Phase 2a IPF study interim data due Q3 2024
Net loss $1.9M for Q1 2024; R&D expenses $0.9M, G&A $1.0M.
-
GRI Bio reports FY2023 net loss of $13.0M; cash runway extended into Q3 2024 after $5.5M offering
Net loss of $13.0M for FY2023; R&D expense $3.2M (up from $0.2M) and G&A $8.2M (up from $2.0M).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material